Radiopharm Theranostics RADX
NASDAQ RADX
$1.44 -0.18 (-11.11%)
As of: Oct 1, 2026 · 10:36 AM EDT

Radiopharm Theranostics (RADX) Non-Current Debt (2024 - 2026)

Updated

Radiopharm Theranostics (RADX) recorded Non-Current Debt of $134,159 in fiscal Q4 2026 (quarter ended Jun 30, 2026), down 27.0% from $183,657 a year earlier.

Analysis

Radiopharm Theranostics (RADX) Non-Current Debt (2024 - 2026) Analysis & Trends

At the end of FY2026 (ended Jun 30, 2026), Radiopharm Theranostics reported Non-Current Debt of $128,449, down 99.6% from FY2025.

  • Across earlier fiscal years, Non-Current Debt came in at $28.68 million in FY2025 (+5.8%) and $27.11 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 37.34 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 62.48 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 51.08 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -108.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 51.86 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 23.83 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 60.50 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Radiopharm Theranostics 5.74 Bn 5.70 Bn 186,835.86 134,159.49
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 134,159.49
Jun 30, 2025 183,656.95
Dec 31, 2024 27.30 Mn
Jun 30, 2024 178,643.67
API Access

Radiopharm Theranostics Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=RADX&period=max&api_key=YOUR_API_KEY